Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010
Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.Breast cancer research and treatment · 2024Pooled it
- Long-term hormone therapy for perimenopausal and postmenopausal women.The Cochrane database of systematic reviews · 2017Pooled it
- Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy.Menopause (New York, N.Y.) · 2020Trial
- Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.JAMA oncology · 2015Trial
- Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.The Lancet. Oncology · 2012Trial
- Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials.Breast cancer research and treatment · 2012Trial
- Trial
- The Role of Estrogen across Multiple Disease Mechanisms.Current issues in molecular biology · 2024Review
- Exploring the Feasibility of Estrogen Replacement Therapy as a Treatment for Perimenopausal Depression: A Comprehensive Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Resveratrol prevents ovariectomy-induced bone quality deterioration by improving the microarchitectural and biophysicochemical properties of bone.Journal of bone and mineral metabolism · 2023Article
- Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study.Journal of the National Cancer Institute · 2023Article
- Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women.Cancers · 2022Review
- Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.The Journal of pathology · 2022Article
- Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.Cancers · 2018Review
- NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.Cancer research · 2017Article
- Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.World journal of gastroenterology · 2016Review
- The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk.Endocrinology and metabolism clinics of North America · 2015Review
- Menopausal hormone therapy and breast cancer mortality: clinical implications.Therapeutic advances in drug safety · 2015Review
- Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.Steroids · 2014Review
- Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.International journal of cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
purposeAs the influence of estrogen alone on breast cancer detection is not established, we examined this issue in the Women's Health Initiative trial, which randomly assigned 10,739 postmenopausal women with prior hysterectomy to conjugated equine estrogen (CEE; 0.625 mg/d) or placebo.
methodsScreening mammography and breast exams were performed at baseline and annually. Breast biopsies were based on clinical findings. Effects of CEE alone on breast cancer detection were determined by using receiver operating characteristic (ROC) analyses of mammogram performance.
resultsAfter a 7.1-year mean follow-up, fewer invasive breast cancers were diagnosed in the CEE than in the placebo group, but the difference was not statistically significant. Use of CEE alone increased mammograms with short-interval follow-up recommendations (cumulative, 39.2% v 29.6.3%; P < .001) but not abnormal mammograms (ie, those suggestive of or highly suggestive of malignancy; cumulative, 7.3% v 7.0%; P = .41). Breast biopsies were more frequent in the CEE group (cumulative, 12.5% v 10.7%; P = .004) and less commonly diagnosed as cancer (8.9% v 15.8%, respectively, with positive biopsies; P = .04). Mammographic breast cancer detection in the CEE group was significantly compromised only in the early years of use.
conclusionCEE alone use for 5 years results in approximately one in 11 and one in 50 women having otherwise avoidable mammograms with short-interval follow-up recommendations or breast biopsies, respectively. Although the breast biopsies on CEE were less commonly diagnosed as cancer, breast cancer detection was not substantially compromised. These findings differ from estrogen-plus-progestin use, for which significantly increased abnormal mammograms and a compromise in breast cancer detection are seen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.